Biohaven Pharmaceuticals
Data Breaches, Cyber Attacks and Security Report

https://biohavenpharma.com  ᛫ 
Last updated March 21, 2020

Biohaven Pharmaceuticals Security Rating

${grade.letter}
${cstarScore}
/ 950

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Biohaven Pharmaceuticals is implementing good security practices.

Company Information

Company:
${companyName}
Valuation:
${marketCap}
Employees:
${employees}
Location:
${country}
CEO:
${ceo}

About Biohaven Pharmaceuticals

Rimegepant (BHV-3000; formerly BMS-927711) is an investigational drug candidate for the treatment of migraine. Originally discovered at Bristol-Myers Squibb, it is currently under development by Biohaven Pharmaceuticals.


Data Breaches and Security News


Security Report for Biohaven Pharmaceuticals

Want a security rating for your organization?

This report shows a preliminary security rating for Biohaven Pharmaceuticals. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.

Get a deeper scan

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Biohaven Pharmaceuticals's security performance with other companies